Dana-Farber Cancer Institute: Colorectal Neoplasms trials
The registry lists 14 Colorectal Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 6No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL TrialRecruitingNCT06565052Not applicable
- Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE TrialRecruitingNCT06202183Not applicable
- Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
- Study of Vitamin D in Untreated Metastatic Colorectal CancerCompletedNCT01516216Phase 2Results posted
- RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal CancerCompletedNCT01058655Phase 1/2Results posted
- UNTIRE: Cancer-related Fatigue With Digital TreatmentWithdrawnNCT05584540Not applicable
- Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE StudyActive, not recruitingNCT05327452Not applicable
- Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
- The Active After Cancer Trial (AACT)Active, not recruitingNCT00548236Not applicable
- ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal CancerCompletedNCT00436072Phase 1
- Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal CancerCompletedNCT00165568Phase 2
- Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00165217Phase 2
- Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerCompletedNCT00123851Phase 2
- Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2